1. Home
  2. IRD vs AAME Comparison

IRD vs AAME Comparison

Compare IRD & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • AAME
  • Stock Information
  • Founded
  • IRD 2018
  • AAME 1968
  • Country
  • IRD United States
  • AAME United States
  • Employees
  • IRD 14
  • AAME N/A
  • Industry
  • IRD
  • AAME Life Insurance
  • Sector
  • IRD
  • AAME Finance
  • Exchange
  • IRD NYSE
  • AAME Nasdaq
  • Market Cap
  • IRD 36.3M
  • AAME 30.3M
  • IPO Year
  • IRD N/A
  • AAME N/A
  • Fundamental
  • Price
  • IRD $1.15
  • AAME $1.68
  • Analyst Decision
  • IRD Strong Buy
  • AAME
  • Analyst Count
  • IRD 1
  • AAME 0
  • Target Price
  • IRD $8.00
  • AAME N/A
  • AVG Volume (30 Days)
  • IRD 154.1K
  • AAME 5.6K
  • Earning Date
  • IRD 02-19-2025
  • AAME 03-31-2025
  • Dividend Yield
  • IRD N/A
  • AAME 2.38%
  • EPS Growth
  • IRD N/A
  • AAME N/A
  • EPS
  • IRD N/A
  • AAME N/A
  • Revenue
  • IRD $8,381,000.00
  • AAME $185,929,000.00
  • Revenue This Year
  • IRD N/A
  • AAME N/A
  • Revenue Next Year
  • IRD $29.37
  • AAME N/A
  • P/E Ratio
  • IRD N/A
  • AAME N/A
  • Revenue Growth
  • IRD N/A
  • AAME 0.35
  • 52 Week Low
  • IRD $0.81
  • AAME $1.26
  • 52 Week High
  • IRD $2.77
  • AAME $3.00
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • AAME 58.51
  • Support Level
  • IRD N/A
  • AAME $1.60
  • Resistance Level
  • IRD N/A
  • AAME $1.72
  • Average True Range (ATR)
  • IRD 0.00
  • AAME 0.10
  • MACD
  • IRD 0.00
  • AAME 0.01
  • Stochastic Oscillator
  • IRD 0.00
  • AAME 73.33

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts. It also provides tailored business automobile insurance coverage, on a multi-year contract basis, to state governments and local municipalities, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance. It earns revenue from the collection of premiums and investment income.

Share on Social Networks: